Abstract: The invention relates to a recombinant Mycobacterium cell for use as an immunotherapeutic agent in the treatment of cancer, particularly in the treatment of solid tumors. More particularly, the invention relates to the immunotherapy of bladder carcinoma.

Abstract: Disclosed herein is a glycocojugate vaccine conferring protection against a Gram negative pathogen infection, a method of manufacturing the glycoconjugate vaccine, and use of the glycocojugate vaccine for treating bacterial infection. The glycocojugate vaccine of the present disclosure has the structure of formula (I), wherein, L is a maleimide-type linker, which is connected to the carrier protein via a maleimide bond formed therebetween; and n and m are respectively an integral or a non-integral number between 2 and 20.

Abstract: The present application relates to immunogenic compositions comprising a mixture of staphylococcal antigens which combines antigen having different functions, for instance, combinations including a staphylococcal extracellular component binding protein and a staphylococcal transporter protein or a staphylococcal extracellular component binding protein and a staphylococcal regulator of virulence or toxin or a staphylococcal transporter protein and a staphylococcal regulator of virulence or toxin. Vaccines, methods of treatment, uses of and processes to make a staphylococcal vaccine are also described.

Abstract: The disclosure provides synthetic (e.g. recombinant) pneumococcal saccharide comprising one or more repeat unit(s)?4)-?-D-Glcp-(1?3)-[[?-L-Rhap-(1?2)]-[Gro-(2?P?3)]-?-D-Galp-(1?4)]-?-L-Rhap-(1?.Also provided are conjugates comprising a ?4)-?-D-Glcp-(1?3)-[[?-L-Rhap-(1?2)]-[Gro-(2?P?3)]-?-D-Galp-(1?4)]-?-L-Rhap-(1?, immunogenic compositions, vaccines and their use in preventing or treating infection by Streptococcus pneumoniae.

Abstract: The invention generally relates to a purified inactivated Zika virus (ZIKV), methods for producing the purified inactivated ZIKV, immunogenic compositions and vaccines comprising the purified inactivated ZIKV and methods for the prevention and/or treatment of infection by ZIKV.

Abstract: Provided herein is a non-natural isolated chicken fibroblast cell that has the characteristics of immortalized growth and supporting replication of Marek's Disease Virus (MDV), wherein number of MDV produced by the cell is at least 1.5-fold greater than the number of the same MDV produced by a DF-1 cell under the same conditions. Also provided herein are methods including producing virus using the cell, determining the number of virus in a sample using the cell, and using the cell to produce protein.

Abstract: An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection.

Abstract: Disclosed are methods for treating a patient suffering from osteogenesis imperfecta comprising administering to the patient a therapeutically effective amount of an anti-sclerostin antibody. Methods for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient by administering to the patient a therapeutically effective amount of an anti-sclerostin antibody are also disclosed. Further disclosed are compositions for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient. The compositions comprise a therapeutically effective amount of an anti-sclerostin antibody. The invention also provides an anti-sclerostin antibody for use in the treatment of osteogenesis imperfecta.

Abstract: The present invention relates to the discovery that inhibition of the interaction between Dickkopf2 (DKK2) and Low-Density Lipoprotein (LDL) Receptor Related Protein 5 (LRP5) and/or inhibition of LRP5 suppresses tumor formation. Thus, in various embodiments described herein, the methods of the invention relate to methods of treating cancer by administering to a patient an effective amount of an inhibiting agent that blocks the interaction between DKK2 and LRP5, methods of treating cancer by administering to a patient an effective amount of a LRP5 depleting agent, methods for providing anti-tumor immunity in a subject, and methods of stimulating a NK and T cell mediated immune response to a cell population or a tissue in a subject. Furthermore, the invention encompasses a pharmaceutical composition for treating cancer.

Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to a method of administering a BCMA-targeting agent which is an anti-BCMA antibody molecule or a recombinant non-antibody protein that binds to BCMA, and a gamma secretase inhibitor.

Abstract: Cancer cells can be synchronized to the G2/M phase by delivering an anti-microtubule agent (e.g., paclitaxel or another taxane) to the cancer cells, and applying an alternating electric field with a frequency between 100 and 500 kHz to the cancer cells, wherein at least a portion of the applying step is performed simultaneously with at least a portion of the delivering step. This synchronization can be taken advantage of by treating the cancer cells with radiation therapy after the combined action of the delivering step and the applying step has increased a proportion of cancer cells that are in the G2/M phase. The optimal frequency and field strength will depend on the particular type of cancer cell being treated. For certain cancers, this frequency will be between 125 and 250 kHz (e.g., 200 kHz) and the field strength will be at least 1 V/cm.

Abstract: A method of cancer hyperthermia therapy includes placing a device including an exogenously-excitable polymeric material at a cancer hyperthermia therapy site of a patient. The method also includes supplying an exogenous energy to the device such that the exogenous energy excites the exogenously-excitable polymeric material at the cancer hyperthermia therapy site to heat the cancer hyperthermia therapy site to a hyperthermia temperature. A method of preparing a polymeric material includes combining an alcohol monomer, a seed of the polymeric material, and an aqueous liquid in a vessel. The method also includes adding an acid monomer to the vessel and supplying an exogenous energy to the vessel. The polymeric material is exogenously excited by the exogenous energy to heat the polymeric material. The method further includes removing water from the vessel and producing the polymeric material, which is a polyester, in the vessel.

Abstract: The present invention relates to compositions and methods for destroying target cells in a patient using photodynamic therapy. In particular, the present invention provides a photosensitizing agent based on a small molecular weight (<50 kDa) protein or peptide or a small molecule that is conjugated to a phthalocyanine dye, such as IRDye® 700DX.

Abstract: The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab).

Abstract: The invention provides stable aqueous pharmaceutical formulations comprising a therapeutic antibody, trehalose, a buffer, and optional surfactant, and having a pH in the range of about 5.5 to about 7.0. The invention also provides methods for making such formulations and methods of using such formulations.

Abstract: An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention is to provide a compact, lightweight prefilled syringe by filling a syringe with the injectable preparation. The present invention provides an injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a specific suspending agent, the composition having a viscosity of 40 pascal-seconds or more in at least one point in the shear rate range of 0.01 to 0.02 s?1 and having a viscosity of 0.2 pascal-seconds or less in at least one point in the shear rate range of 900 to 1,000 s?1, as measured.

Abstract: Provided is a biodegradable drug delivery composition comprising: (i) a mixture of at least three different block copolymers, wherein each block copolymer is: (a) a biodegradable triblock copolymer having the formula: Av-Bw-Ax wherein A is a polyester and B is polyethylene glycol and v and x are from 1 to 3,000 and w is from 3 to 300 and v=x or v?x; or (b) a biodegradable diblock copolymer having the formula: Cy-Az wherein A is a polyester and C is an end-capped polyethylene glycol and y=2 to 250 and z=1 to 3,000; and wherein the mixture comprises at least one (a) and at least one (b); and the weight ratio between (a) and (b) is 1:19 to 5:1; and for at least one of the copolymers according to (a) or (b) A is poly(lactic-co-glycolic acid) (PLGA); and (ii) at least one pharmaceutically active ingredient.

Abstract: The present document is directed to a pharmaceutical composition comprising at least one non-ionic cellulose ether, wherein said composition has a viscosity of 35000 cP or more, an osmolality of from about 10 to about 300 mOsmol/kg, and a pH of from about 3 to about 4. The composition may be used in the treatment and/or prevention of a climacteric disorder, wherein said climacteric disorder is a selected from the group consisting of vaginal dryness, vaginal irritation, vaginal itching, dysuria, dyspareunia, and/or vaginal bleeding during and/or after sexual intercourse and any combination thereof.

Abstract: Among the various aspects of the present disclosure is the provision of compositions and methods for targeted treatment and imaging of cancers or tumors.

Abstract: The present invention relates to compounds of Formulas I-IV, which are salts of special lipid mediators of inflammation, compositions containing same, and methods of using same in the treatment of various diseases and disorders characterized by chronic or excessive inflammation, or both.

Abstract: The present invention relates to nanostructures for penetrating deep into cancer tissues, and more particularly, to nanostructures capable of selectively delivering nanoparticles and drugs to cancer tissues because it is possible to intelligently control the release of the nanoparticles and the drugs depending on the pH condition of the cancer tissues and also having high nanoparticle and drug delivery efficiency because it is possible for the nanoparticles to penetrate deep into the cancer.

Abstract: The present disclosure relates to a formulation including: a) a dendron of Formula I; b) at least one bio-therapeutic; c) at least one buffer; and d) at least one salt, wherein the bio-therapeutic to dendron molar ratio is in the range of 1:0.5-1:3. The dendron stabilizes the bio-therapeutic in the formulation at a temperature of up to 55° C.

Abstract: The present invention demonstrates that erythropoietin (EPO)-receptor (EPOR) is a malignant myeloma biomarker of sensitivity to EPO treatment and, itself a target for myeloma treatment. A low EPOR level in a myeloma cells of the subject indicates non-response to EPO treatment. Patients having high EPOR level in myeloma cells can be effectively treated with EPO, in particular an EPO derivatized with polysialic acid.

Abstract: The teachings provide methods of delivering active agents that are conjugated with delivery systems that increase the half-life, and reduce the immunogenicity, of the active agents. Delivery systems and methods of making and using the delivery systems are also provided. The delivery systems have (i) a ligand that is selective for an endogeneous plasma protein in the serum of a subject; and, (ii) a linker configured for operatively attaching the ligand covalently to an active agent to increase the half-life of the active agent in the serum.

Abstract: A composition for the delivery of a nucleic acid compound is provided which comprises a cationic peptide or polymer and a lipidoid compound. The nucleic acid compound may be any chemically modified or unmodified DNA or RNA. The amount of the lipidoid in the composition is preferably low, relative to the cationic peptide or polymer.

Abstract: Compounds for targeted immunotherapy, compositions comprising the compounds and use of the compounds in the treatment of diseases such as cancer are disclosed. The compounds having the structure of formula TM-Ln-AM, wherein TM is a targeting moiety, AM is an activating moiety that is capable of activating a human dendritic cell, NK cell, or tumor cell, or a combination thereof, Ln is a linker, and n is an integer selected from 0 and 1.

Abstract: The present disclosure provides particles with a polymeric core containing a pharmaceutically active agent; and an antibody fragment conjugated to the surface of the particle, wherein the antibody fragment targets an endogenous immune cell subset (e.g., an endogenous T-cell or a myeloid-derived suppressor cell). The present invention provides methods for forming and methods for using the particles. The particles described herein may be useful in treating and/or preventing proliferative disease, inflammatory disease, or neoplastic disorders (e.g., cancer, autoimmune diseases). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a particle described herein.

Abstract: Provided is a method for modifying a chimeric antigen receptor-modified T cell (CAR-T cell). The method comprises expressing an SCFV-CDS TM-4-1BB-CD3? molecule in a T cell. The CAR-T cell prepared using the method can specifically recognize and bind to a tumor cell with elevated expression of a ROBO1 protein, and can be used to prevent and treat a corresponding tumor-related disease.

Abstract: The invention is directed to a method for cancer treatment and prevention, specifically, a method of targeting and delivering therapeutic agents and/or imaging reagent to cells expressing Purinergic Receptor P2Y G-Protein Coupled 1 (P2RY1).

Abstract: The disclosure provides, methods for preparing scavenging particles, as well as methods for attaching capture agents to the particles. The disclosure further provides compositions that bind to and inhibit the biological activity of soluble biomolecules, as well as pharmaceutical compositions thereof. The compositions may comprise a plurality of particles that specifically bind a target, such as a soluble biomolecule or a biomolecule on the surface of a pathogen, to inhibit the target (or pathogen) from interacting with other molecules or cells. Also provided herein are a number of applications (e.g., therapeutic applications) in which the compositions are useful.

Abstract: A fusion protein comprises a nanocage monomer; and an antibody or fragment thereof linked to the nanocage monomer, the antibody or fragment thereof comprising a first member of a binding pair; wherein a plurality of the fusion proteins self-assemble to form a nanocage in which a plurality of the antibodies or fragments thereof decorate the exterior surface of the nanocage, whereby the first member of the binding pair is exposed for interacting with a second member of a binding pair.

Abstract: Nucleic acid sequences encoding improved Herpes Simplex Virus Thymidine Kinases are provided, including their use in diagnostic and therapeutic applications. The thymidine kinases may be mutated using conservative mutations, non-conservative mutations, or both. Also provided are gene therapeutic systems, including viral and retroviral particles.

Abstract: The present disclosure provides compositions and methods for the treatment of PPARG activated cancer. For example, the present disclosure provides PPARG signaling modulators for the treatment of bladder cancer. In particular, therapeutic and/or prophylactic compositions and uses of PPARG inverse-agonists are described.

Abstract: The present invention relates to the prevention and/or treatment of retinal dystrophy in a patient, including Leber congenital amaurosis (LCA).

Abstract: Conformationally restricted cyanine fluorophores, as well as methods of making and using the compounds, are described. The conformationally restricted cyanine fluorophores have a chemical structure according to Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof: wherein A is and wherein each “*” designates an attachment point of A.

Abstract: Compounds, compositions, kits and methods for performing angiography related to ocular diseases, are disclosed.

Abstract: Described is a versatile surface modification approach to, for example, modularly and orthogonally functionalize nanoparticles (NPs) such as, for example, PEGylated nanoparticles, ith various types of different functional ligands (functional groups) on the NP surface. It enables the synthesis of, for example, penta-functional PEGylated nanoparticles integrating a variety of properties into a single NP, e.g., fluorescence detection, specific cell targeting, radioisotope chelating/labeling, ratiometric pH sensing, and drug delivery, while the overall NP size remains, for example, below 10 nm.

Abstract: The present invention includes a composition, method, method of making, and a kit for using an enteric contrast agent formulation comprising an enteric contrast medium comprising particles comprising atoms of an element with an atomic number from 70 to 77, and a pharmaceutically acceptable vehicle in which the particles are dispersed.

Abstract: Provided are aromatic compounds, phospholipid-polymer-aromatic conjugates comprising the aromatic compounds, and liposome compositions including the phospholipid-polymer-aromatic conjugates. The liposomal compositions may be useful for imaging of Alzheimer's Disease, for example, imaging of the amyloid-? plaque deposits characteristic of Alzheimer's Disease.

Abstract: Provided herein are methods, compositions and kits for use in the site-specific labeling of glycoproteins comprising a combination of enzyme-mediated incorporation of modified sugars comprising a chemical handle and cycloaddition chemistry with a labeling molecule comprising a reactive group, a metal ion chelator, and/or a fluorophore.

Abstract: Methods for processing tissue are provided. In some embodiments, the methods comprise methods for decellularizing tissue samples by applying high hydrostatic pressure to the tissues samples. In some embodiments, the methods comprise methods for thawing tissue samples and/or reducing the bioburden in a sample by applying high hydrostatic pressure to the tissue samples.

Abstract: The invention concerns a disinfection device includes a disinfection chamber having an interior volume and a radiation source coupled to the interior volume. The radiation source is arranged to emit disinfecting radiation into the interior volume when in operation. A disinfection program in the disinfection chamber is arranged to control the radiation source to emit the disinfecting radiation according to parameters determined based on at least one of a three dimensional model of the disinfection chamber and a three dimensional model of a target article to be disinfected. The three dimensional model of the disinfection chamber is formed using data collected by operating at least one radiation source in a data collection disinfection chamber, or by providing a disinfection chamber model having a virtual interior volume. The three dimensional model of the target article to be disinfected is formed by providing a target article model having a virtual surface.

Abstract: A hybrid germicidal irradiation apparatus, method, and system for dual-band germicidal irradiation. A first plurality of emitters and a second plurality of emitters may be coupled to a housing configured to be coupled to a ceiling of an interior room. The first plurality of emitters and the second plurality of emitters may be operable to emit UV-C radiation at a wavelength of about 265 nanometers and near-UV radiation at a wavelength of about 405 nanometers, respectively. One or more radiation sensors are configured to measure the amount of UV-C light or near UV-C light reflected from a target surface. A controller may be communicably engaged with the radiation sensors to calculate an amount of UV-C radiation and near-UV radiation delivered to a target surface or interior space.

Abstract: A medical instrument processor includes an enclosure, a liquid distribution system, and a disinfectant concentration measuring subsystem. The enclosure is configured to hold a medical instrument. The liquid distribution system is configured to deliver a disinfection solution to a medical instrument within the enclosure. The liquid distribution system has a liquid outlet. The disinfectant concentration measuring subsystem includes a first mixing chamber in fluid communication with the liquid outlet, a pump that is configured to simultaneously pump the disinfection solution and the reagent solution into the first mixing chamber, and a concentration analysis assembly that is operable to determine a concentration of disinfectant in a sample solution that is output from the first mixing chamber. The reservoir is in fluid communication with the first mixing chamber.

Abstract: An adsorbent and photocatalytic decontamination gel consisting of a colloidal solution comprising, preferably consisting of: 8% to 30% by weight, preferably 10% to 30% by weight, more preferably 15% to 20% by weight, better still 15% to 20% by weight, the value 15% being excluded, even better still 16% to 20% by weight, for example 20% by weight of TiO2, optionally doped, relative to the weight of the gel; optionally 0.01% to 10% by weight, preferably 0.1% to 5% by weight, relative to the weight of the gel, of at least one dye and/or of at least one pigment; optionally 0.1% to 2% by weight, relative to the weight of the gel, of at least one surfactant; optionally 0.05% to 5% by weight, preferably 0.05% to 2% by weight, relative to the weight of the gel, of at least one superabsorbent polymer; and the balance of solvent.

Abstract: A pathogen-deactivating fibrous material is coated with salt crystals or salt crystal layer. The salt crystals or coating on the supporting fibrous material layer dissolves upon exposure to pathogenic aerosols and recrystallizes during evaporation of water from the pathogenic aerosols. Recrystallization of the salt deactivates pathogens. The pathogen-deactivating fibrous material can be used in a sanitizing fabric, an air filtering device, such as respiratory devices, masks, furnace filter devices, air conditioning device, vehicle cabin filter device, etc., and can provide a universal personal protection for preventing infections.

Abstract: Embodiments relate generally to systems and methods for sterilizing a container comprising a liquid, where a method may comprise placing the container within an autoclave vessel; pressurizing the autoclave vessel to an initial pressure, by pressurizing the autoclave vessel with a clean gas via a first valve; after pressurizing the autoclave vessel to the initial pressure, heating the autoclave vessel to sterilize the liquid within the container within the autoclave vessel; controlling the pressure within the autoclave vessel while heating the autoclave vessel to maintain a pressure within ±10% of the initial pressure via a second valve; and cooling the autoclave vessel after sterilization.

Abstract: A biological indicator analyzer includes a plurality of wells, a plurality of organism detector features, and a user input feature such as a touch screen. Each well is configured to receive a respective biological indicator. Each organism detector feature is configured to detect whether a biological indicator disposed in a corresponding well of the plurality of wells contains a living organism. The touch screen is configured to receive user input and provide information to the user indicating a status of biological indicator analysis. The biological indicator analyzer may be used to analyze a biological indicator that was positioned in a sterilization chamber of a sterilizing cabinet along with at least one medical device that is to be sterilized. The analysis may indicate whether the sterilization cycle in the sterilization chamber as successful.

Abstract: A biological indicator with variable resistance may be controlled by moving a cap or housing of the biological indicator to cause the size of vents that allow flow of sterilant through the housing to decrease or increase in effective size. An indicator window may show a user the current resistance of the biological indicator, and may also show a readable indicator that may be captured by a scanner to allow a sterilizing cabinet to identify the current resistance. When the level of resistance shown by the readable indicator is not compatible with a sterilization cycle selected by a user, the procedure may be delayed and a notification provided to the user that a problem exists. The readable indicator may be a passive tag with a memory that allows information to be read and written, so that the biological indicator may carry data from one device to another.

Abstract: A sterilization container with a sensor module for monitoring the environmental characteristics internal to the container. The sensor module includes a normally closed end bore. A sensor is disposed in the closed end void space. Other sensors also part of the module monitor the pressure and temperature of the environment inside the container. Based on the measurements of the environment in the container and the environment within the closed end void space it is possible to determine the extent to which the container is filled with saturated steam.